

D-mine[®] Care

**Working In Partnership for a Patient
Centred Service**



D-mine[®] Care is available to all patients in the UK on Dacepton[®] therapy free of charge. The service is designed to work in partnership with your specialist team to ensure you are well supported while on Dacepton[®] therapy

Nursing Services

D-mine[®] Care have a team of skilled registered nurses who have experience looking after people with Parkinson's who are on Apomorphine Therapy. The D-mine[®] Nurses can help the Parkinson's specialist to initiate, monitor and support the patient and their family while they are on Dacepton[®] therapy. The D-mine[®] Nurses are also able to work closely with the primary care team and provide training and education to District Nurses and other community nurse teams.

About the D-mine[®] Nurse Team

- The D-mine[®] Nurse Team work in partnership with patients and healthcare professionals to ensure they deliver care efficiently and effectively
- Our nurses are registered with the NMC and operate within the Nursing Code of Conduct and Professional Standards of Practice
- They receive ongoing training and continued professional development to keep their professional registration and standard of practice up to date
- The team work within the General Data Protection Regulation to ensure patient and healthcare professional personal data is kept securely and confidentially
- The team are located around the UK covering all regions

The D-mine[®] Nurse Team Service Provision

- Our nurses can provide a comprehensive pre-assessment and education for patients who are considering Dacepton[®] therapy
- Aim to enhance the patient experience and confidence when starting Dacepton[®], improving the experience they have while on treatment
- Scheduled visits are offered to patients while receiving Dacepton[®] therapy
 - Pre-assessment and education
 - Dose response and initiation in specialist clinic setting
 - During the first year of therapy at regular intervals. Patient will have at least eight home/telephone visits in partnership with the Parkinson's Nurse Specialist and consultant
 - Patients requiring additional support can receive extra visits from the D-mine[®] Nurses or by trained support nurses
- Patient records are kept electronically on a secure internet database. Information stored on the database will include:
 - All clinical interactions
 - Any correspondence sent to relevant healthcare professionals
 - Any correspondence received
 - Care management plan agreed with relevant specialist
 - Risk assessments
 - Medication and Dacepton[®] dosage record
- Where appropriate the D-mine[®] Nurse can also assist with clinic reviews
- Comprehensive training can be arranged for all healthcare professionals and for people who care for anyone receiving Dacepton[®] therapy
Training includes:
 - How to use the devices (Pump and Pen)
 - Skin management
 - Dacepton[®] and possible advantages/side effects

Home Care Delivery Service

- Homecare Delivery can be arranged for anywhere in the UK
- It is free of charge and efficient with support available from the dedicated homecare team
- Prescriptions can be managed by the Homecare team to provide a seamless service and ensure supply is sufficient
- Any other equipment used such as disposals and equipment for disposal of sharps can be delivered to any address
- Further information and materials about the homecare and the D-mine[®] Nurse Team can be discussed with a D-mine[®] Nurse Advisor



Equipment Provided

The D-mine[®] Care Package provides some equipment free of charge when a patient starts Dacepton[®] therapy.

This includes the following:

- D-mine[®] pump loaned for free with a signed loan agreement
- First D-mine[®] pen distributed free of charge. Subsequent pens, if required, can be prescribed
- Infusion lines provided free of charge (one line per day)
- Accessories for pump are provided free of charge such as holder for pump and shoulder strap
- Two rechargeable batteries provided for pump with a charging docking station
- If a pump is faulty, a further pump can be distributed free of charge via a courier service within a set time frame

D-mine[®] Care Support Contact Information

The D-mine[®] Care Package provides patients and professionals with two dedicated phone lines

The D-mine[®] Technical Support line is open 24hrs a day, 365 days a year and is a free phone number. The number is for technical pump issues such as:

- Any queries regarding the D-mine[®] pump or pen.
- D-mine[®] pump and pen training/support for yourself, healthcare professional or family/carer.
- Arrange contact with you D-mine[®] Care Nurse.

The D-mine[®] care support line is open 9am-5pm Monday to Friday and 9am – 1pm on a Saturday. This line can offer support for the following:

- Prescription queries.
- Homecare queries.
- Signposting to correct health professional.

Please note the telephone numbers and emails for helplines below

To refer a patient to the D-mine[®] Care service:

Email: dminecare.referral.uk@everpharma.com

Free Phone: 0800 254 0175

Or contact your local D-mine[®] Care Nurse Advisor

Nurse advisors can be emailed via NHS.net (email available on request)

For support related to Dacepton[®] therapy or D-mine[®] equipment call the D-mine[®] Care support line on 0800 254 0175 or email dminecare.uk@everpharma.com

For Medical Information please contact on 0800 254 0174



Dacepton® 10mg/ml solution for injection in cartridge
Apomorphine hydrochloride

PRESCRIBING INFORMATION

Consult Summary of Product Characteristics before prescribing.

Uses Treatment of motor fluctuations ("on-off" phenomena) in patients with Parkinson's disease which are not sufficiently controlled by oral anti-Parkinson medication. Dosage and Administration Patients selected for treatment with Dacepton should be able to recognise the onset of their "off" symptoms and be capable of injecting themselves or else have a responsible carer able to inject for them when required. Apomorphine should be initiated in the controlled environment of a specialist clinic. The patient should be supervised by a physician experienced in the treatment of Parkinson's disease (e.g. neurologist). Patients treated with apomorphine will usually need to start domperidone at least two days prior to initiation of therapy. The domperidone dose should be titrated to the lowest effective dose and discontinued as soon as possible. The daily dose of Dacepton varies widely between patients, typically within the range of 3-30 mg, given as 1-10 injections and maximum 12 separate injections per day. The total daily dose of apomorphine hydrochloride hemihydrate should not exceed 100 mg and that individual bolus injections should not exceed 10 mg. The D-mine Pen that is required for the application of Dacepton solution for injection in cartridge is not suitable for patients needing doses above 6 mg/bolus. The D-mine device differs from other devices available on the market, patients and carers should be adequately trained for its use. Do not use if the solution has turned green. The solution should be inspected visually prior to use. Only clear, colourless and particle free solution should be used. Please refer to the Summary of Product Characteristics for full details before initiating therapy. Contraindications Hypersensitivity to the apomorphine HCl or to the product ingredients. Patients with respiratory depression, dementia, psychotic diseases or hepatic insufficiency. Apomorphine hydrochloride hemihydrate must not be administered to patients who have an "on" response to levodopa which is marred by severe dyskinesia or dystonia. Concomitant use with ondansetron. Children and adolescents under 18 years of age. Pregnancy and lactation Apomorphine should not be used in pregnancy unless clearly necessary. Breast-feeding should be avoided during apomorphine HCl therapy.

Interactions Patients should be monitored for potential interactions during initial stages of apomorphine therapy. Caution should be taken when apomorphine is used with other medications that have a narrow therapeutic window. It should be noted that there is potential for interaction with neuroleptic and antihypertensive agents. It is recommended to avoid the administration of apomorphine with other drugs known to prolong the QT interval.

Side Effects Very common Hallucinations, injection site reactions particularly with continued use, these may include subcutaneous nodules, induration, erythema, tenderness and panniculitis. Various other local reactions (such as irritation, itching, bruising and pain) may also occur. Local induration and nodules (usually asymptomatic) often develop at subcutaneous site of injection, leading to areas of erythema, tenderness, induration and panniculitis. Common Neuropsychiatric disturbances (including transient mild confusion and visual hallucinations), transient sedation that usually resolves with continued treatment, apomorphine is associated with somnolence, dizziness/light-headedness, yawning, nausea and vomiting particularly during initiation of treatment if domperidone is omitted. Prescribers should consult the Summary of Product Characteristics in relation to other side effects
Presentation and Basic NHS Cost Dacepton cartridges contain 3ml apomorphine hydrochloride 10mg/ml as follows: basic NHS cost per 5-pack of cartridges £123.00. NHS cost per pen £100.

Marketing Authorisation Numbers:

PL 40369/0007

Legal Category POM

Date of last revision: August 2018

For further information please contact: EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Medical Information on 0800 254 0174 or info.uk@everpharma.com

EVP-009a Date of preparation: October 2018

Dacepton 5 mg/ml solution for infusion

Apomorphine hydrochloride

PRESCRIBING INFORMATION

Consult Summary of Product Characteristics before prescribing.

Uses Treatment of motor fluctuations ("on-off" phenomena) in patients with Parkinson's disease which are not sufficiently controlled by oral anti-Parkinson medication

Dosage and Administration Patients selected for treatment with Dacepton 5 mg/ml solution for infusion should be able to recognise the onset of their "off" symptoms and be capable of injecting themselves or else have a responsible carer able to inject for them when required. Patients treated with apomorphine will usually need to start domperidone at least two days prior to initiation of therapy. The domperidone dose should be titrated to the lowest effective dose and discontinued as soon as possible. Before the decision to initiate domperidone and apomorphine treatment, risk factors for QT interval prolongation in the individual patient should be carefully assessed to ensure that the benefit outweighs the risk. Apomorphine should be initiated in the controlled environment of a specialist clinic. The patient should be supervised by a physician experienced in the treatment of Parkinson's disease (e.g. neurologist). The patient's treatment with levodopa, with or without dopamine agonists, should be optimised before starting treatment. Dacepton 5 mg/ml is presented in a pre-filled vial and is intended for prolonged subcutaneous infusion only. Hourly infusion rates range between 1 mg and 4 mg (0.2 ml and 0.8 ml), equivalent to 0.014 - 0.06 mg/kg/hour and in almost all cases should run for waking hours only. The total daily dose of apomorphine hydrochloride should not exceed 100 mg. **Special Warnings and Precautions** Contraindicated in children and adolescents under 18 years of age. Caution is recommended when initiating therapy in the elderly because of the risk of postural hypotension. Administer with caution to patients with renal, pulmonary or cardiovascular disease and those prone to nausea and vomiting. Because of the risk of hypotension care should be taken in administering apomorphine to patients taking vasoactive medicinal products. An ECG should be performed prior to treatment, during treatment initiation and as clinically indicated thereafter. In some patients neuropsychiatric disturbances may be precipitated. Apomorphine may be associated with somnolence and episodes of sudden deep sleep and patients must be warned when operating machinery or driving. Patients should be regularly monitored for the onset of impulse control disorders. **Side Effects** Very common Hallucinations, injection site reactions particularly with continued use, these may include subcutaneous nodules, induration, erythema, tenderness and panniculitis. Various other local reactions (such as irritation, itching, bruising and pain) may also occur. Local induration and nodules (usually asymptomatic) often develop at subcutaneous site of injection, leading to areas of erythema, tenderness, induration and panniculitis. Common Neuropsychiatric disturbances (including transient mild confusion and visual hallucinations), transient sedation that usually resolves with continued treatment, apomorphine is associated with somnolence, dizziness/light-headedness, yawning, nausea and vomiting particularly during initiation of treatment if domperidone is omitted. Prescribers should consult the Summary of Product Characteristics in relation to the treatment of overdose and for details of other side effects
Presentation and Basic NHS Cost. 20 ml vial containing 100 mg apomorphine hydrochloride hemihydrate each 1 ml contains 5 mg apomorphine hydrochloride basic NHS cost for 5-pack of 20ml Vials £145.00.

Marketing Authorisation Numbers:

PL 40369/0003

Legal Category POM

Date of last revision: October 2018

For further information please contact: EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Medical Information on 0800 254 0174 or info.uk@everpharma.com

EVP-009b Date of preparation: October 2018